IDH1 and glioma: As shown in Figure 6, TERT promoter mutations (HR = 2.30; 95% CI, 1.09–4.86; P = 0.029) and long RTL (HR = 2.55; 95% CI, 1.18–5.52; P = 0.018) were two predictors of poor survival in glioma patients receiving radiotherapy as an independently variable with respect to WHO grade, KPS score, IDH1 mutations and MGMT methylation, respectively.